QPPV.COM KNOWLEDGE ASSESSMENT

Ustekinumab Biosimilars: IL-12/23 Biology, Interchangeability and Product Pharmacovigilance

Test your understanding of the concepts covered by Ustekinumab Biosimilars: IL-12/23 Biology, Interchangeability and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which set of evidence most appropriately addresses residual uncertainty after analytical similarity has been established?

Only a comparison of package design and tablet colour Pharmacokinetics, immunogenicity assessment and, where needed, comparative clinical evidence A requirement that every patient receive both products simultaneously Post-marketing spontaneous reports alone before authorisation

Question 2 of 10 Which statement accurately describes the US regulatory status of Wezlana?

It is authorised only as a generic small-molecule medicine It is FDA-approved as a biosimilar to and interchangeable with Stelara It is approved only as an investigational reference product It is automatically substitutable in every US state without regard to law

Question 3 of 10 What is the most accurate description of ustekinumab's mechanism of action?

It binds p40 and prevents IL-12 and IL-23 from engaging the IL-12Rβ1 receptor chain It binds IL-12Rβ1 and permanently removes the receptor from immune cells It directly neutralises IL-17 and interferon-gamma after they are released It broadly suppresses all cytokine production through nonspecific cytotoxicity

Question 4 of 10 Which overall workflow is most appropriate for a suspected ustekinumab biosimilar safety event?

Identify the product, confirm jurisdiction and indication, reconstruct switching and administration, define the clinical event, assess alternatives and preserve batch information Assign causality from the product name, then request only the patient's age Treat all ustekinumab products as one undifferentiated exposure and exclude device information Focus exclusively on whether the product is labelled interchangeable

Question 5 of 10 Which statement best reflects the appropriate causal interpretation of mechanism in pharmacovigilance?

A biologically plausible mechanism proves that the product caused the event Mechanism can inform plausibility and case prioritisation but cannot by itself establish causation Mechanism is irrelevant when assessing adverse events Mechanism proves that all events reported with the reference product must be caused by the biosimilar

Question 6 of 10 Why must intravenous and subcutaneous ustekinumab presentations be distinguished in medication-safety assessment?

They contain different active substances They have different administration routes, uses and error modes despite containing ustekinumab The subcutaneous presentation is not a biological medicine The intravenous presentation is used only for psoriasis

Question 7 of 10 A safety report states only that the patient received 'ustekinumab' after a pharmacy substitution. What is the most important PV follow-up?

Assume that the product was the reference medicine because it was prescribed first Close the report because biosimilars are expected to have no clinically meaningful differences Identify the actual brand, relevant suffix, batch, dose timing and switch history Classify the event as a biosimilar-specific reaction immediately

Question 8 of 10 Which distinction is particularly important when evaluating injection-related reports?

Local injection-site reactions should be distinguished from systemic hypersensitivity All injection-site pain should be classified as anaphylaxis Device leakage always demonstrates altered antibody potency Systemic hypersensitivity can be assessed without considering onset after dosing

Question 9 of 10 A report mentions headache and 'possible posterior reversible encephalopathy syndrome' but contains no neurological examination or imaging information. What is the best assessment approach?

Confirm the syndrome based on headache alone Reject the report because rare neurological events are not relevant Seek syndrome-level clinical and imaging evidence before interpreting it as that condition Treat every headache after ustekinumab as a serious neurological signal

Question 10 of 10 Which aggregate finding would most strongly justify a product-specific investigation?

Expected infections occurring across several ustekinumab products at similar patterns A cluster of administration failures associated with one device configuration and batch A single mild headache with no product information Known class-level events reported without dates or indication

Ustekinumab Biosimilars: IL-12/23 Biology, Interchangeability and Product Pharmacovigilance

Cookie Settings